This study used network meta-analysis (NMA) to inform and compare the number needed to treat (NNT), number needed to harm (NNH), and cost per improved outcome (CPIO) associated with more recently approved treatments for anti-acetylcholine receptor antibody-positive (anti-AChR Ab+) generalized myasthenia gravis (gMG). Clinical trials of neonatal Fc receptor (FcRn) inhibitors, efgartigimod intravenous (IV) and rozanolixizumab, and complement inhibitors, ravulizumab and zilucoplan, versus placebo (with background conventional treatment) were included in the primary NMA to compare efficacy and safety outcomes. The outputs from the NMAs were used to estimate NNT and NNH of each treatment versus placebo. CPIO (2024 USD) was estimated for a ≥ 3- or ≥ 5-point reduction from baseline in Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores. Sensitivity analyses were performed adding efgartigimod PH20 subcutaneous (SC) and eculizumab to the NMA. Efgartigimod IV had the lowest NNT versus placebo for achieving a ≥ 3- and ≥ 5-point reduction in QMG, as well as a ≥ 5-point reduction in MG-ADL, whereas rozanolixizumab had the lowest NNT for a ≥ 3-point reduction in MG-ADL. The NNH versus placebo was similar across comparator treatments. Efgartigimod IV had the lowest CPIO among all treatments for all assessed efficacy outcomes. Sensitivity analyses yielded results consistent with primary analysis and indicated that efgartigimod PH20 SC had comparable NNT and CPIO values to efgartigimod IV, whereas eculizumab had comparable NNT and higher CPIO values compared to other complement inhibitors. FcRn inhibitors and complement inhibitors assessed in this study all demonstrated clinical benefit in terms of NNT as well as an acceptable safety profile in terms of NNH. Within the limitations of this meta-analysis, efgartigimod was associated with a favorable benefit–risk profile as well as a better economic value compared to ravulizumab, rozanolixizumab, and zilucoplan as treatments for anti-AChR Ab+ gMG.

A. Gordon Smith

Gil I. Wolfe

Ali A. Habib

Cynthia Z. Qi

Hongbo Yang

Mandy Du

Xin Chen

Deborah Gelinas

Edward Brauer

Glenn Phillips

Francesco Saccà

Advances in Therapy

ADVANCES IN THERAPY 是一本国际、同行评审、快速出版（2 周内同行评审，接受后 3-4 周出版）期刊，致力于出版高质量的临床（所有阶段）、观察性、真实世界和围绕所有治疗领域的治疗和干预措施（包括设备）的发现、开发和使用进行健康结果研究。还鼓励与诊断和诊断、药物经济学、公共卫生、流行病学、生活质量以及患者护理、管理和教育相关的研究。该杂志吸引了广大医疗保健专业人士的兴趣，并发表原创研究、评论、通讯和信件。该杂志由全球读者阅读，并接收来自世界各地的投稿。 ADVANCES IN THERAPY 将考虑所有科学合理的研究，无论是正面的、证实性的还是负面的数据。无论提交的内容是否与国际和/或特定国家的受众有关，都欢迎提交，这在研究人员试图针对更具体的患者群体时至关重要。这种包容性的方法使期刊能够协助传播所有科学和道德上合理的研究。

Advances in Therapy is an international, peer-reviewed, rapid publication journal dedicated to publishing high-quality clinical research (at all stages), observational studies, real-world evidence, and health outcomes research related to interventions (including devices) across all therapeutic areas. The journal encourages research related to diagnostics, pharmacoeconomics, public health, epidemiology, quality of life, as well as patient care, management, and education. It attracts a wide audience of healthcare professionals and publishes original research, reviews, communications, and letters. The journal has a global readership and accepts submissions from around the world. Advances in Therapy considers all scientifically valid research, whether positive, confirmatory, or negative data. Submissions are welcome regardless of their relevance to international and/or specific national audiences, which is crucial when researchers aim to target more specific patient populations. This inclusive approach allows the journal to assist in disseminating all scientifically and ethically sound research.

《Advances in Therapy》是一本国际同行评审的快速出版期刊，致力于发表高质量的临床研究（涵盖所有阶段）、观察性研究、真实世界研究以及与所有治疗领域相关的干预措施（包括设备）的健康结果研究。期刊鼓励与诊断、药物经济学、公共卫生、流行病学、生活质量以及患者护理、管理和教育相关的研究。该杂志吸引了广泛的医疗保健专业人士的关注，发表原创研究、评论、通讯和信件。它的读者遍布全球，欢迎来自世界各地的投稿。《Advances in Therapy》将考虑所有科学合理的研究，无论是正面、证实性还是负面数据。无论提交的内容是否与国际或特定国家的受众相关，均欢迎投稿，这在研究者针对更具体的患者群体时尤为重要。这种包容性的方法使期刊能够协助传播所有科学和伦理上合理的研究。

Category	Quartile
医学	3
医学, 医学研究与实验	3
医学, 药学	3

Risk–Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
PHARMACOLOGY & PHARMACY	2